A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors ; day:16 ; month:4 ; year:2019 ; pages:1-10
Investigational new drugs ; (16.4.2019), 1-10
- Creator
-
Sharman, Jeffrey P.
Wheler, Jennifer J.
Einhorn, Lawrence
Dowlati, Afshin
Shapiro, Geoffrey I.
Hilton, John
Burke, John M.
Siddiqi, Tanya
Whiting, Nancy
Jalal, Shadia I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10637-019-00768-6
- URN
-
urn:nbn:de:101:1-2019051019340584326150
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sharman, Jeffrey P.
- Wheler, Jennifer J.
- Einhorn, Lawrence
- Dowlati, Afshin
- Shapiro, Geoffrey I.
- Hilton, John
- Burke, John M.
- Siddiqi, Tanya
- Whiting, Nancy
- Jalal, Shadia I.
- SpringerLink (Online service)
Other Objects (12)
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Der CD30-Antikörper Brentuximab Vedotin zeigt umfassende anti-proliferative Wirkung in Keimzelltumor-Zelllinien
Brentuximab Vedotin (CD30+ Hodgkin-Lymphom, Erstlinie) : Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V
Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction
Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin : a monocentric retrospective analysis of twelve patients
Polatuzumab Vedotin: First Global Approval
Analyse der CD30-Funktion mittels agonistischer Antikörper und einem CD30-Liganden-Fusionsprotein
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Der CD30-Antikörper Brentuximab Vedotin zeigt umfassende anti-proliferative Wirkung in Keimzelltumor-Zelllinien
Brentuximab Vedotin (CD30+ Hodgkin-Lymphom, Erstlinie) : Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V
Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction
Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin : a monocentric retrospective analysis of twelve patients
Polatuzumab Vedotin: First Global Approval
Analyse der CD30-Funktion mittels agonistischer Antikörper und einem CD30-Liganden-Fusionsprotein
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin
Brentuximab Vedotin beim Hodgkin Lymphom und systemischen ALCL : CD30-Positive Lymphone
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Der CD30-Antikörper Brentuximab Vedotin zeigt umfassende anti-proliferative Wirkung in Keimzelltumor-Zelllinien
Brentuximab Vedotin (CD30+ Hodgkin-Lymphom, Erstlinie) : Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V
Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction
Long term survival, time to next treatment and CD30 expression in patients with advanced CD30+ cutaneous T-cell lymphoma treated with Brentuximab vedotin : a monocentric retrospective analysis of twelve patients
Polatuzumab Vedotin: First Global Approval
Analyse der CD30-Funktion mittels agonistischer Antikörper und einem CD30-Liganden-Fusionsprotein
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial